Stocks / Healthcare

Vera Therapeutics Inc

VERA Stock Report
Current Price
XXXX
Analyst Target Price
$62.73
Market Cap
XXXX
Updated
September 15, 2025
Analysts
14

Vera Therapeutics Inc Stock Overview

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company's lead product candidate consists of … More details ➜
1 Year Price Range
Low $18.53 Current High $51.61
PinkLion Scores

Fundamentals Summary

P/E Ratio
-
P/S Ratio
-
Net Income
Revenue
Market Cap

Net Income & Revenue

Last Reported Earnings
June 30, 2025
Earnings per share (EPS) $-3.59
Gross Margin -
Net Profit Margin -
Debt/Equity Ratio 0.93%

Dividends

Current Dividend Yield
-
Payout Ratio
-
Forward Dividend Yield
-

Price History

Track historical stock performance, price trends, and volatility for VERA to see how the stock has performed over time.
YTD
1 Year
5 Years
All

Valuation Summary

We estimate a fair price for VERA by projecting its future cash flows and discounting them back to today with a XXXXX model.

About the Company

IPO Date
May 14, 2021
Employees
192
Sector
Healthcare
Industry
Biotechnology
Country
USA
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company's lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.